- 801. Beta-Interferon Gene Positive-Regulatory Domain I Binding Factor
- [Expression by human PRDM1 Gene increased on virus induction, 789-aa 88-kDa PR-Domain Zinc Finger Protein 1 is a transcriptional repressor containing a SET domain and 4 C2H2-type zinc fingers. PRDM1 specifically binds to the PRDI (positive regulatory domain I) element of the beta-IFN gene promoter and represses beta-interferon gene expression. PRDM1 also drives maturation of B lymphocytes into Ig secreting cells. (NCI) ( NCI )] (UMLS (NCI) C0254341) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 843. Better eye: severe vision impairment; lesser eye: total vision impairment
- [ ] (UMLS (ICD9CM) C0392563) =Disease or Syndrome
|
- 802. Beta-methyl Cyclodextrin
- [A molecular host acting as carrier. Beta-methyl cyclodextrin is part of a group of cyclic polysaccharides containing 6 to 8 glucose units in alpha-(1,4) linkage. The assembled cyclodextrin framework possesses a hydrophobic internal cavity which can include various small molecules and a peripheral structure containing a large number of hydroxyl groups making the molecule water soluble. Beta-cyclodextrin is employed for numerous applications to enhance solubility and availability of various water-soluble and water-insoluble pharmacological agents. ( NCI )] (UMLS (NCI) C0667093) =Carbohydrate
| - 844. Better eye: severe vision impairment; lesser eye; impairment not further specified
- [ ] (UMLS (ICD9CM) C0392570) =Disease or Syndrome
|
- 803. Beta-Microseminoprotein
- [Encoded by human MSMB Gene (Ig Binding Factor Family, Beta-Microseminoprotein Family), 12.8 kD (precursor) secreted Beta-Microseminoprotein (isoforms PSP94 and PSP57) is expressed in prostate, liver, kidney, breast, penis, pancreas, esophagus, stomach, duodenum, colon, trachea, lung, salivary glands, and fallopian tube. PSP94 is also expressed in lung and breast; PSP57 is found in kidney and bladder. The 94-amino acid seminal protein is derived from a pre-polypeptide of 114 amino acids. Specific receptors are found on spermatozoa and in the prostate. The protein may have inhibin-like activity; it may act as an autocrine paracrine factor in uterine, breast, and other female reproductive tissues and may inhibit pituitary secretion of FSH. (from Swiss-Prot, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0525289) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 845. Better eye: total vision impairment; lesser eye: total vision impairment
- [ ] (UMLS (ICD9CM) C0155022) =Disease or Syndrome
|
- 804. Beta-R1
- [Encoded by INF gamma- and INF beta-induced human CXCL11 Gene (Intercrine Alpha/Chemokine CXC Family) in leukocytes, pancreas, liver, astrocytes, thymus, spleen, lung, placenta, prostate, small intestine, and keratinocytes, secreted 94-aa 10-kD (precursor) Small Inducible Cytokine B11 is a chemotactic ligand for 7-transmembrane, G protein-coupled receptor CXCR3 that regulates activated T cell response. (NCI) ( NCI )] (UMLS (NCI) C1335987) Chemokine (C-X-C Motif) Ligand 11;
CXCL11;
H174;
Interferon-Gamma-Inducible Protein-9;
Interferon-Inducible T-Cell Alpha Chemoattractant;
IP-9;
I-TAC;
Small Inducible Cytokine B11;
Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member 11;
Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member 9B;
=Amino Acid, Peptide, or Protein; Immunologic Factor | - 846. Better--use when direction not relevant
- (UMLS (HL7) C0694716) =Laboratory or Test Result ;
=Abnormal flags;
|
- 805. Beta-ser-interferon
- [A recombinant form of the natural Interferon beta that varies in the amino acid sequence and lacks the carbohydrate side chain. Clinical Use: Multiple Sclerosis. ( NCI )] (UMLS (NCI) C0244714) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
=interferon beta 1b;
=INTERFERON BETA-1B,RECOMBINANT 0.3 MG | - 847. between breakfast and lunch
- (UMLS (HL7) C1549045) =Temporal Concept =Event related period;
|
- 806. Betacellulin Gene
- [This gene plays a role in regulating the growth of retinal pigment epithelial cells and vascular smooth muscle cells. ( NCI )] (UMLS (NCI) C1332453) BTC;
BTC Gene;
=Gene or Genome ;
| - 848. between dinner and the hour of sleep
- (UMLS (HL7) C1549046) =Temporal Concept =Event related period;
|
- 807. Betadine
- (UMLS (NCI) C0699524) =Organic Chemical; Pharmacologic Substance
| - 849. between lunch and dinner
- (UMLS (HL7) C1549044) =Temporal Concept =Event related period;
|
- 808. betadren
- [ ] (UMLS (CSP) C0700771) =Organic Chemical; Pharmacologic Substance
| - 850. Between Meals
- [In between meals. ( NCI )] (UMLS (NCI) C0587121) =Temporal Concept ;
|
- 809. Betagan
- (UMLS (NCI) C0591174) =Organic Chemical; Pharmacologic Substance
| - 851. between meals (from lat. inter cibus)
- (UMLS (HL7) C1549043) =Temporal Concept =Event related period;
|
- 810. Betaglycan
- [Encoded by human TGFBR3 Gene, 849-aa 93-kDa (precursor) Transforming Growth Factor Beta Receptor III is a membrane-bound or soluble glycoprotein heavily modified by glycosaminoglycan groups, with regions of similarity to endoglin, and containing a ZP domain. Lacking a recognizable signaling domain, TGFBR3 binds to TGF-Beta and may be a TGFBR and FGFR receptor accessory molecule; it may capture and retain TGF-Beta for presentation to signaling receptors. TGF-beta is a multifunctional cytokine that modulates cell differentiation, cell cycle progression, cellular migration, adhesion, and extracellular matrix production. TGFBR3 can also bind inhibin and function as coreceptor with ActRII; inhibin forms crosslinked complexes with TGFBR3 and ActRII. TGFBR3 also binds beta arrestin 2, which appears to trigger cytoplasmic phosphorylation by TGFBR2. (NCI) ( NCI )] (UMLS (NCI) C0106158) =Amino Acid, Peptide, or Protein; Receptor
| - 852. Beuren syndrome
- [syndrome of elfinlike facies, mental retardation, growth deficiency, cardiovascular anomalies, and idiopathic infantile hypercalcemia. ( CSP )] (UMLS (CSP) C0175702) =Disease or Syndrome ;
=Aortic Stenosis, Supravalvular;
Chromosomal anomalies;
syndrome;
congenital disorder;
Chromosomal Disorders, Nervous System;
|
- 811. Betaherpesvirinae
- [highly species-specific group; have an affinity for salivary glands or kidneys; inclusion bodies are found in the nuclei and cytoplasm late in infection. ( CSP )] (UMLS (CSP) C0206560) =Virus =herpes virus;
=CMV | - 853. Bevacizumab/Capecitabine
- (UMLS (NCI) C0935797) =Therapeutic or Preventive Procedure
|
- 812. BETAMETHASONE
- [A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions. ( NCI )] (UMLS (NCI) C0005308) =Steroid; Pharmacologic Substance; Hormone
| - 854. Bevacizumab/Capecitabine/Oxaliplatin
- (UMLS (NCI) C1328044) =Therapeutic or Preventive Procedure ;
|
- 813. Betamethasone Acetate
- (UMLS (NCI) C0005310) =Steroid; Pharmacologic Substance; Hormone
| - 855. Bevacizumab/Carboplatin/Paclitaxel
- (UMLS (NCI) C0935884) =Therapeutic or Preventive Procedure
|
- 814. Betamethasone Benzoate
- (UMLS (NCI) C0005311) =Steroid; Pharmacologic Substance ;
| - 856. Bevacizumab/Cetuximab
- (UMLS (NCI) C1328136) =Therapeutic or Preventive Procedure ;
|
- 815. BETAMETHASONE SODIUM PHOSPHATE
- [The disodium salt of the 21-phosphate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone sodium phosphate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions. ( NCI )] (UMLS (NCI) C0700603) =Organic Chemical; Pharmacologic Substance ;
=BETAMETHASONE;
=BETAMETHASONE SODIUM PHOSPHATE 3 MG/ML;
BETAMETHASONE SODIUM PHOSPHATE 4 MG/ML;
| - 857. Bevacizumab/Cetuximab/Irinotecan
- (UMLS (NCI) C1328137) =Therapeutic or Preventive Procedure ;
|
- 816. betaretrovirus
- [genus of the family retroviridae consisting of viruses with either type B or type D morphology; includes a few exogenous, milk transmitted and endogenous viruses of mice; associated with mammary carcinoma and T- lymphoma. ( CSP )] (UMLS (CSP) C0950105) Retroviruses, Type B, Mammalian;
Type B Mammalian Retrovirus;
Type B Virus =Virus ;
=Retroviridae;
=Bittner virus;
Mason Pfizer monkey virus;
type D oncovirus;
| - 858. Bevacizumab/Cisplatin/Gemcitabine
- (UMLS (NCI) C1134521) =Therapeutic or Preventive Procedure
|
- 817. betatron
- [ ] (UMLS (CSP) C0005319) =Manufactured Object
| - 859. Bevacizumab/Cyclophosphamide
- (UMLS (NCI) C1328090) =Therapeutic or Preventive Procedure; ;
|
- 818. BETAZOLE
- [A histamine H2 agonist used clinically to test gastric secretory function. ( MSH )] (UMLS (NCI) C0005321) =Organic Chemical; Pharmacologic Substance ;
| - 860. Bevacizumab/Cytarabine/Idarubicin
- (UMLS (NCI) C1134480) =Therapeutic or Preventive Procedure
|
- 819. betelnut
- [ ] (UMLS (CSP) C0684282) =Organic Chemical; Pharmacologic Substance ;
| - 861. Bevacizumab/Docetaxel
- (UMLS (NCI) C1134527) =Therapeutic or Preventive Procedure
|
- 820. bethanechol
- [A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, cardiac rate changes, and bronchial spasms. ( MSH )] (UMLS (CSP) C0053526) =Organic Chemical; Pharmacologic Substance ;
=Bethanechol Compounds;
[AU300] PARASYMPATHOMIMETICS (CHOLINERGICS) =2-[(Aminocarbonyl)oxy]-N,N,N-trimethyl-1-propanaminium Chloride;
BETHANECHOL 25 MG | - 862. Bevacizumab/Docetaxel/Doxorubicin
- (UMLS (NCI) C0935900) =Therapeutic or Preventive Procedure
|
- 821. BETHANIDINE SULFATE
- (UMLS (NCI) C0282073) =Organic Chemical; Pharmacologic Substance ;
| - 863. Bevacizumab/Docetaxel/Estramustine
- (UMLS (NCI) C0935852) =Therapeutic or Preventive Procedure
|
- 822. Bethesda unit
- [1 ( HL7V3.0 )] (UMLS (HL7) C0439151) =Quantitative Concept =UnitOfMeasureAtomInsens;
UnitOfMeasureAtomSens | - 864. Bevacizumab/Doxorubicin
- (UMLS (NCI) C1327827) =Therapeutic or Preventive Procedure ;
|
- 823. Betoptic
- (UMLS (NCI) C0699055) =Organic Chemical; Pharmacologic Substance
| - 865. Bevacizumab/Erlotinib
- (UMLS (NCI) C1327881) =Therapeutic or Preventive Procedure ;
|
- 824. Betta splendens
- [ ] (UMLS (CSP) C0599049) =Fish
| - 866. Bevacizumab/Fluorouracil
- (UMLS (NCI) C1327837) =Therapeutic or Preventive Procedure; ;
|
- 825. better
- [Better (of severity or nominal observations) ( HL7V3.0 )] (UMLS (HL7) C1550462) =Idea or Concept =ObservationInterpretationChange;
| - 867. Bevacizumab/Fluorouracil/Hydroxyurea
- (UMLS (NCI) C1134475) =Therapeutic or Preventive Procedure
|
- 826. Better eye: moderate vision impairment; lesser eye: blind, not further specified
- [ ] (UMLS (ICD9CM) C0392566) =Disease or Syndrome
| - 868. Bevacizumab/Fluorouracil/Irinotecan/Leucovorin Calcium
- (UMLS (NCI) C0935737) =Therapeutic or Preventive Procedure
|
- 827. Better eye: moderate vision impairment; lesser eye: impairment not further specified
- [ ] (UMLS (ICD9CM) C0392571) =Disease or Syndrome
| - 869. Bevacizumab/Fluorouracil/Leucovorin Calcium
- (UMLS (NCI) C0935792) =Therapeutic or Preventive Procedure
|
- 828. Better eye: moderate vision impairment; lesser eye: moderate vision impairment
- [ ] (UMLS (ICD9CM) C0271239) =Disease or Syndrome
| - 870. Bevacizumab/Fluorouracil/Leucovorin Calcium/Oxaliplatin
- (UMLS (NCI) C1134498) =Therapeutic or Preventive Procedure
|
- 829. Better eye: moderate vision impairment; lesser eye: near-total vision impairment
- [ ] (UMLS (ICD9CM) C0392568) =Disease or Syndrome
| - 871. Bevacizumab/Gemcitabine
- (UMLS (NCI) C1134551) =Therapeutic or Preventive Procedure ;
|
- 830. Better eye: moderate vision impairment; lesser eye: profound vision impairment
- [ ] (UMLS (ICD9CM) C0392569) =Disease or Syndrome
| - 872. Bevacizumab/Imatinib Mesylate
- (UMLS (NCI) C1328110) =Therapeutic or Preventive Procedure; ;
|
- 831. Better eye: moderate vision impairment; lesser eye: severe vision impairment
- [ ] (UMLS (ICD9CM) C0392572) =Disease or Syndrome
| - 873. Bevacizumab/Interferon Alfa
- (UMLS (NCI) C1134504) =Therapeutic or Preventive Procedure
|
- 832. Better eye: moderate vision impairment; lesser eye: total vision impairment
- [ ] (UMLS (ICD9CM) C0392567) =Disease or Syndrome
| - 874. Bevacizumab/Irinotecan
- (UMLS (NCI) C0935793) =Therapeutic or Preventive Procedure
|
- 833. Better eye: near-total vision impairment; lesser eye: near-total vision impairment
- [ ] (UMLS (ICD9CM) C0271220) =Disease or Syndrome ;
| - 875. Bevacizumab/Paclitaxel
- (UMLS (NCI) C1134547) =Therapeutic or Preventive Procedure
|
- 834. Better eye: near-total vision impairment; lesser eye: not further specified
- [ ] (UMLS (ICD9CM) C0521709) =Disease or Syndrome ;
| - 876. Bevacizumab/PEG-Interferon Alfa-2b
- (UMLS (NCI) C1327908) =Therapeutic or Preventive Procedure ;
|
- 835. Better eye: near-total vision impairment; lesser eye: total vision impairment
- [ ] (UMLS (ICD9CM) C0392558) =Disease or Syndrome ;
| - 877. Bevacizumab/Thalidomide
- (UMLS (NCI) C0935722) =Therapeutic or Preventive Procedure
|
- 836. Better eye: profound vision impairment; lesser eye: near-total vision impairment
- [ ] (UMLS (ICD9CM) C0392561) =Disease or Syndrome ;
| - 878. Bevacizumab/Vinorelbine
- (UMLS (NCI) C0935867) =Therapeutic or Preventive Procedure ;
|
- 837. Better eye: profound vision impairment; lesser eye: not further specified
- [ ] (UMLS (ICD9CM) C0392559) =Disease or Syndrome ;
| - 879. beverage
- [liquids suitable for drinking. ( CSP )] (UMLS (CSP) C0005329) =Food
|
- 838. Better eye: profound vision impairment; lesser eye: profound vision impairment
- [ ] (UMLS (ICD9CM) C0271224) =Disease or Syndrome ;
| - 880. Bexarotene/Carboplatin/Paclitaxel
- (UMLS (NCI) C1134643) =Therapeutic or Preventive Procedure
|
- 839. Better eye: profound vision impairment; lesser eye: total vision impairment
- [ ] (UMLS (ICD9CM) C0392560) =Disease or Syndrome ;
| - 881. Bexarotene/Cisplatin/Vinorelbine
- (UMLS (NCI) C1134565) =Therapeutic or Preventive Procedure
|
- 840. Better eye: severe vision impairment; lesser eye: near-total vision impairment
- [ ] (UMLS (ICD9CM) C0392564) =Disease or Syndrome
| - 882. Bexarotene/Interferon Alfa
- (UMLS (NCI) C0338343) =Therapeutic or Preventive Procedure ;
|
- 841. Better eye: severe vision impairment; lesser eye: profound vision impairment
- [ ] (UMLS (ICD9CM) C0392565) =Disease or Syndrome
| - 883. Bexxar
- (UMLS (NCI) C0919272) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
|
- 842. Better eye: severe vision impairment; lesser eye: severe vision impairment
- [ ] (UMLS (ICD9CM) C0271236) =Disease or Syndrome
| - 884. [11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester
- [A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica. Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis. Bruceantin also has antiamoebic and antimalarial activity. (NCI04) ( NCI )] (UMLS (NCI) C0054160) =Organic Chemical; Pharmacologic Substance
|
home
